Cantor Fitzgerald Estimates TNGX FY2025 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tango Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($1.39) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Several other brokerages have also issued reports on TNGX. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a research report on Friday, November 8th. B. Riley reduced their price target on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Finally, Guggenheim lowered their price objective on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics currently has an average rating of “Buy” and a consensus price target of $13.14.

Tango Therapeutics Price Performance

TNGX stock opened at $3.08 on Wednesday. Tango Therapeutics has a 1 year low of $2.59 and a 1 year high of $13.01. The firm has a 50-day moving average of $3.30 and a 200 day moving average of $6.60. The company has a market cap of $330.85 million, a P/E ratio of -2.61 and a beta of 0.81.

Insider Transactions at Tango Therapeutics

In related news, insider Boxer Capital Management, Llc sold 3,080,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $3.14, for a total value of $9,671,200.00. Following the completion of the transaction, the insider now directly owns 3,610,642 shares in the company, valued at $11,337,415.88. The trade was a 46.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mace Rothenberg acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $3.78 per share, for a total transaction of $37,800.00. Following the completion of the transaction, the director now directly owns 31,250 shares of the company’s stock, valued at $118,125. The trade was a 47.06 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TNGX. Barclays PLC grew its position in Tango Therapeutics by 78.3% in the 3rd quarter. Barclays PLC now owns 126,281 shares of the company’s stock worth $972,000 after purchasing an additional 55,470 shares during the period. Geode Capital Management LLC increased its position in Tango Therapeutics by 11.6% during the third quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock valued at $10,538,000 after acquiring an additional 142,710 shares during the last quarter. XTX Topco Ltd lifted its holdings in Tango Therapeutics by 340.1% in the third quarter. XTX Topco Ltd now owns 44,191 shares of the company’s stock valued at $340,000 after acquiring an additional 34,150 shares during the period. Sphera Funds Management LTD. purchased a new position in Tango Therapeutics in the third quarter worth about $385,000. Finally, State Street Corp grew its stake in shares of Tango Therapeutics by 26.8% during the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after purchasing an additional 489,949 shares during the period. Institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.